Atara advances CAR T technology with IND clearance

By The Science Advisory Board staff writers

September 9, 2020 -- Atara Biotherapeutics said that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for ATA2271, a next-generation, autologous mesothelin-targeted chimeric antigen receptor (CAR) T-cell therapy for patients with advanced mesothelioma.

As a result, Atara will initiate an open-label, single-arm phase I trial for the therapy, which uses 1XX CAR signaling and programmed death-1 dominant negative receptor checkpoint inhibition technologies. Atara is developing ATA2271 in collaboration with Memorial Sloan Kettering Cancer Center.

In preclinical studies, ATA2271 was associated with less cell exhaustion, improvements in functional persistence, serial cell killing, and enhanced in vivo efficacy when compared with first-generation mesothelin CAR T therapy, according to the company. Atara said that these effects were maintained through multiple redosings.

Carma Cell Therapies expands phase I trial of cell therapy
Carma Cell Therapies said it has expanded the phase I trial of its Mcy-M11 lead anti-mesothelin messenger RNA chimeric antigen receptor- peripheral blood...
Transarterial chemoperfusion shows promise in mesothelioma patients
According to research presented during a recent virtual session of the Society of Interventional Radiology, there has been progress on a novel treatment...
CAR-T cell therapy research shows encouraging signs for mesothelioma patients
Every year, nearly 3,000 new cases of mesothelioma are diagnosed in the United States. While this is just a small percentage of overall cancer diagnoses,...
Personalized Treatments and Vaccines Offer Hope for Beating Rare Cancers
Immunotherapy is undoubtedly one of the most influential and exciting fields of our time, with an ability to unlock the foundations of diseases and move...

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter